Our editor-in-chief rates the first year of response to the pandemic.
Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS
Advertisement
Jason C. Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, is a clinical professor at Temple University (TU) School of Pharmacy and a clinical pharmacy specialist in infectious diseases at Temple University Hospital in Philadelphia, Pennsylvania. He also is director of the PGY2 Residency in Infectious Diseases Pharmacy at TU.
Articles by Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS
The US Food and Drug Administration approved imipenem-cilastatin-relebactam to treat complicated intra-abdominal infections and complicated urinary tract infections in adults with limited treatment options.
Advertisement
Advertisement
Advertisement
Trending on Contagion Live
1
US Completely Revamps Childhood Vaccine Schedule to Resemble Small European Country
2
Multicomponent Nudges Increase Influenza Immunization
3
The Great Debate: To Extend or Not Extend?
4
How Should We Interpret the Changes to the Childhood Vaccine Schedule?
5